Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGAVE trial of octreotide for refractory bleeding from gastric antral vascular ectasia
NL-OMON49336Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in gastric antral vascular ectasia (GAVE), sponsored by Radboud University Medical Center. Primary endpoints: Change in transfusion requirements and Successful response rate. Started Apr 2021; status: completed.
02
Drugs
octreotide
03
Conditions
gastric antral vascular ectasia (GAVE)
Beyond the preview
Go deeper on NL-OMON49336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49336.